Overall, this work demonstrates that Bcl-XL upregulation contributes to acquired resistance of DLBCL cancer cells towards venetoclax and that antagonizing Bcl-XL can resensitize such cells towards venetoclax. This evidence concerns the gene BCL2L1 and diffuse large B-cell lymphoma.